Clinical Indication
The specific medical condition and patient population a BCI is intended to help, which frames the entire trial and regulatory case. Current implanted BCIs target severe motor and communication impairment: tetraplegia from cervical spinal-cord injury, locked-in or near-locked-in states and progressive paralysis in amyotrophic lateral sclerosis (ALS), brainstem stroke, and other causes of anarthria (loss of speech). The indication determines the relevant benefit — restoring communication, digital access, or limb and robotic control — and the comparator standard of care, such as eye-tracking or partner-assisted scanning for communication.
Indication choice is strategic as well as clinical. A narrow, severe indication with high unmet need and few alternatives strengthens the benefit–risk argument for an invasive device and may qualify for expedited regulatory programs, whereas broadening to milder impairment raises the bar because safer non-invasive options already exist and the tolerable risk is lower.
Choosing anarthria in ALS as the indication targets people who have lost speech but retain intact motor and speech cortex, for whom the comparator is a slow eye-tracking speller. That severity and the weakness of alternatives make an invasive speech BCI's benefit–risk case defensible in a way it would not be for someone with mild dysarthria.
The severity of the indication, and the poverty of alternatives, is what licenses an invasive device.
Use outside the approved indication is off-label; current BCI indications are deliberately very narrow and severe, and generalizing claims beyond them is not warranted.